Oncology Reviews (Dec 2011)

Is more better than less? Caveats from bevacizumab and cetuximab combination in colorectal cancer

  • Camillo Porta

DOI
https://doi.org/10.4081/oncol.2009.1
Journal volume & issue
Vol. 3, no. 1

Abstract

Read online

In the past few years, impressing improvements have been made in the treatment of advanced colorectal cancer. Following decades of modest achievements, in which it was just a matter of dose and schedule for 5-FU and leucovorin—the only treatment then available—first, the development of irinotecan and oxaliplatin, and then the use of the two biologicals, bevacizumab and cetuximab, have dramatically improved the life expectancy of our colorectal cancer patients...